Obesity Management

New research indicates semaglutide reduced albuminuria and body weight in CKD patients without diabetes, highlighting its potential renal benefits.

Time-restricted eating, even without calorie restriction, improved glycemic control and cardiometabolic health in patients with metabolic syndrome.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

The new guidance reviews existing tools for weight management and provides recommendations for their use in clinical practice in patients with obesity and kidney disease.

A new study finds visceral adipose tissue and subcutaneous adipose tissue are linked to chronic musculoskeletal pain in both sexes but have a stronger association in females.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

Semaglutide lowers rates of cardiovascular and COVID-19-related deaths in patients with overweight/obesity, offering promising cardio-metabolic and non-cardiovascular benefits.

A new study revealed children who go from normal weight to overweight have a greater risk of atopic dermatitis than obese children who maintain their weight.

A new analysis suggests HbA1c may be more informative to fatty liver disease severity than BMI, and should be included in screenings.

Eli Lilly's tirzepatide showed a 38% reduction in heart failure outcomes and improved symptoms in adults with HFpEF and obesity in the phase 3 SUMMIT trial.

New study finds semaglutide may reduce smoking urge in type 2 diabetes patients, decreasing tobacco use disorder medical encounters by up to 32%.

An analysis using records from 40 million US patients highlights the surge in new GLP-1 receptor agonist use, with semaglutide dominating new prescriptions since 2020.

A STEP-HFpEF analysis suggests semaglutide 2.4 mg (Wegovy) confers benefit across the spectrum of NYHA functional class among patients with obesity-related HFpEF.

A study of 18,000 patients showed tirzepatide (Mounjaro) led to more significant weight loss than semaglutide (Ozempic) in adults with overweight or obesity.

MOMENTUM trial data shows pemvidutide reduced body weight by 15.6%, with 78.1% fat loss, highlighting the GLP-1/Glucagon receptor agonist's ability to achieve significant weight reduction and minimal muscle loss.

In retrospective, observational research at ADA 2024, real-world weight loss was linked to a reduction in the risk of obesity-related cancers.

Tirzepatide reduces OSA severity by 30 events/hour and achieves remission in up to 51% of patients with obesity, per SURMOUNT-OSA study results from Eli Lilly and Company.

New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.

With agents like semaglutide and tirzepatide becoming household drug names, Peterson discusses the short-term future of incretin drug development.

Contrary to previous research, findings point to similar decreases in weight and improvements in glucose homeostasis between time-restricted eating and usual eating pattern groups.

The American College of Physicians released new recommendations for the management of type 2 diabetes with inadequate glycemic control using metformin or other first-line therapies.

Topline data from the SURMOUNT-OSA studies provide insight into the effects of tirzepatide in OSA with obesity, with Lilly disclosing plans for a regulatory submission mid-year.

The STEP HFpEF DM trial at ACC.24 shows significant improvements in symptoms among patients with obesity-related HFpEF and diabetes mellitus.

A recap of the biggest FDA news and decisions in cardiovascular medicine from the first 3 months of 2024, with commentary on recent announcements by Deepak Bhatt, MD, MPH, MBA.

On March 07, 2024, Novo Nordisk provided updates on semaglutide 2.4 mg as well as the development programs cagrisema, monlunabant, and amycretin.

In our endocrinology month in review for February 2024, we are spotlighting trending studies and new data in endocrinology, the latest news surrounding tirzepatide, and a recap of the 4 episodes of our flagship endocrinology podcast launched during the last month.

Viking Therapeutics' dual GLP-1/GIP receptor agonist VK2735 showed promising weight reduction in the phase 2 VENTURE trial, with the 15 mg dose contributing to a 14% reduction in body weight from baseline to week 13.

Survodutide, a dual agonist from Boehringer Ingelheim and Zealand Pharma, was associated with MASH resolution without worsening fibrosis among 83% of participants in a phase 2 trial.

A recent survey indicates many US adults are unaware of their vital health metrics, highlighting the need for increased education on heart disease prevention.